However, as far as we know, it is the first case series of COVID-19 patients treated with IgM and IgA enriched immunoglobulin G. Indeed, the differences recorded in terms of death likelihood on day 7 and above all, between expected and recorded mortality (VLAD) may provide an intriguing suggestion on the management of SARS-CoV-2 related SIRS. The gene discussed is CD79A; the disease is COVID-19.